Dr. Thomas O. Kleen serves as the Chief Scientific Officer and Principal Consultant at BioLab Services LLC, where he leverages his extensive expertise in immunology and biotechnology to drive innovative solutions in the rapidly evolving landscape of cancer immunotherapy and inflammatory diseases. With over 20...
Dr. Thomas O. Kleen serves as the Chief Scientific Officer and Principal Consultant at BioLab Services LLC, where he leverages his extensive expertise in immunology and biotechnology to drive innovative solutions in the rapidly evolving landscape of cancer immunotherapy and inflammatory diseases. With over 20 years of experience in both scientific and executive roles, Dr. Kleen has established himself as a leading figure in the field, particularly in the areas of immuno-oncology and the monitoring of cell-mediated immunity (CMI) and biomarkers. His dual citizenship in Germany and the USA enriches his perspective, allowing him to navigate and bridge diverse scientific and business environments across continents.
At BioLab Services, Dr. Kleen is currently spearheading several key projects aimed at enhancing the efficacy of therapeutic vaccines and advancing translational research initiatives. His strategic focus on high-throughput screening and protein chemistry has led to the development of novel approaches for assessing immune responses in patients undergoing cancer treatment. Dr. Kleen’s out-of-the-box thinking and ability to foster business relationship management have been instrumental in building collaborations with start-ups and established companies alike, facilitating the translation of groundbreaking research into viable clinical applications.
Moreover, his proficiency in flow cytometry and grant applications underscores his commitment to advancing scientific knowledge and securing funding for innovative projects. As a trusted advisor, Dr. Kleen continues to mentor emerging scientists and entrepreneurs, ensuring that the next generation of biotech leaders is equipped with the skills and insights necessary to navigate the complexities of the industry. His holistic approach to scientific leadership not only drives project success but also contributes to the broader mission of improving patient outcomes through cutting-edge immunological research.
